[{"Assets_0_Q2_USD":461578000.0,"CommonStockSharesOutstanding_0_Q2_shares":19669000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":60340000.0,"NetIncomeLoss_1_Q2_USD":4145000.0,"NetIncomeLoss_2_Q2_USD":30156000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":19549000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":19487000.0,"StockholdersEquity_0_Q2_USD":436210000.0,"EarningsPerShareBasic_1_Q2_USD":0.21,"EarningsPerShareBasic_2_Q2_USD":1.55,"Ticker":"ENTA","CIK":"1177648","name":"ENANTA PHARMACEUTICALS INC","OfficialName":"Enanta Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20190331","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1492537180.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20190510"}]